Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.72, $0.36 better than the analyst estimate of $2.36. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1 billion.

GUIDANCE:

Charles River Laboratories sees FY2023 EPS of $10.50-$10.70, versus the consensus of $10.56.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.